KMT2A and acute myeloid leukemia: However, administration of fibronectin to mice with BCR-ABL1+ B-cell acute lymphoblastic leukemia (Fig. S7B) [23] or MLL-AF9+ AML (Fig. S7C) [20, 42] did not lead to significant differences in survival.